3. Guardant Health Inc. (NASDAQ:GH)
Guardant Health, Inc. (NASDAQ: GH) takes third place as one of the strongest publicly traded companies in liquid biopsy and precision oncology.
The company develops blood-based tests that analyze genetic material released by cancer cells. Its products can help identify appropriate treatments, monitor patients for cancer recurrence and screen certain individuals for early signs of disease.
Artificial intelligence and machine learning are important because the company must distinguish meaningful cancer-related signals from enormous amounts of biological information. As its testing volumes increase, the resulting data can potentially improve product performance and strengthen its competitive position.
Second-quarter 2026 revenue surged 44% to $335 million. Oncology revenue increased 38% to approximately $219.1 million, while screening revenue grew by more than 250% to $52.9 million.
The Shield colorectal cancer screening test was a major contributor. Quarterly Shield volume reached approximately 66,000 tests, compared with around 16,000 during the prior-year period.
Management increased its full-year revenue guidance by $40 million to approximately $1.35 billion, representing expected annual growth of between 36% and 38%.
These results suggest that Guardant Health, Inc. (NASDAQ: GH) is moving from technological promise toward large-scale commercial adoption. Its products now address multiple stages of cancer care, from screening to treatment selection and recurrence monitoring.
The risks remain considerable. The company recorded a second-quarter net loss of approximately $120.1 million, compared with a $99.9 million loss one year earlier. Commercial expansion and marketing for Shield continue to require substantial spending.
The company is also dealing with a patent dispute that could result in damages and continuing royalty obligations. While management plans to challenge the ruling, investors must include that legal uncertainty in their assessment.
Guardant Health, Inc. (NASDAQ: GH) still earns third place because few artificial intelligence healthcare companies combine comparable revenue growth with such a large medical opportunity. If Shield gains broader insurance coverage and oncology testing continues expanding, the company could become an increasingly important part of cancer diagnosis and monitoring.
